Apatinib for EGFR-TKIs resistant NSCLC patients: Initial clinical experience.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e14059
Abstract: e14059Background: The 3rd generation TKI is still not available for Chinese NSCLC patients with EGFR-mutant who develop acquired resistance following treatment with 1st EGFR tyrosine kinase inhibit... read more here.
Keywords: apatinib egfr; egfr tkis; nsclc patients; tkis resistant ... See more keywords